Trials / Withdrawn
WithdrawnNCT00488995
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients
A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if CP-675,206, a monoclonal antibody to CTLA4, is safe and well-tolerated, reduces viral load, and improves immune function in patients infected with HIV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-675,206 |
Timeline
- Start date
- 2007-07-01
- First posted
- 2007-06-20
- Last updated
- 2015-03-11
Source: ClinicalTrials.gov record NCT00488995. Inclusion in this directory is not an endorsement.